NAKA vs HIMS vs JPM vs TDOC vs OPRX

For growth investors, Hims & Hers Health, Inc.

(HIMS) is the stronger pick with 59. 0% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 9x versus Hims & Hers Health, Inc. at 59. 2x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +150. 0%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: JPM returned +475. 6% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately 206% more volatile than JPM relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 20% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Hims & Hers Health, Inc.

(HIMS) is pulling ahead at 59. 0% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: OptimizeRx Corporation grew EPS 124. 5% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — HIMS leads at 73. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5.

6x forward P/E versus 14. 3x for JPMorgan Chase & Co. — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 219. 5% to $17. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. NAKA, HIMS, TDOC, OPRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +475. 6% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +475. 6%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NAKA (Financial Services) and HIMS (Healthcare) and JPM (Financial Services) and TDOC (Healthcare) and OPRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; JPM is a large-cap deep-value stock; TDOC is a small-cap quality compounder stock; OPRX is a small-cap high-growth stock. JPM pays a dividend while NAKA, HIMS, TDOC, OPRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.